Zobrazeno 1 - 10
of 93
pro vyhledávání: '"Hwa-ping Feng"'
Autor:
Andrew F. Shorr, Christopher J. Bruno, Zufei Zhang, Erin Jensen, Wei Gao, Hwa-Ping Feng, Jennifer A. Huntington, Brian Yu, Elizabeth G. Rhee, Carisa De Anda, Sumit Basu, Marin H. Kollef
Publikováno v:
Critical Care, Vol 25, Iss 1, Pp 1-12 (2021)
Abstract Background The randomized, double-blind, phase 3 ASPECT-NP trial evaluated the efficacy of 3 g of ceftolozane/tazobactam (C/T) versus 1 g of meropenem infused every 8 h for 8 to 14 days for treatment of adults with hospital-acquired bacteria
Externí odkaz:
https://doaj.org/article/3b53978e253247d8b28a3333ab805866
Autor:
Nancy Reau, Michael N. Robertson, Hwa‐Ping Feng, Luzelena Caro, Wendy W. Yeh, Bach‐Yen T. Nguyen, Janice Wahl, Eliav Barr, Peggy Hwang, Stephanie O. Klopfer
Publikováno v:
Hepatology Communications, Vol 1, Iss 8, Pp 757-764 (2017)
Concomitant proton pump inhibitor (PPI) use reduces plasma concentrations of certain nonstructural protein 5A inhibitors, which are key components of modern hepatitis C infection (HCV) treatments. These reduced concentrations may decrease efficacy, l
Externí odkaz:
https://doaj.org/article/4c7209c5aab146baa45be70dea5608b3
Autor:
Wei, Gao, Yogesh T, Patel, Zufei, Zhang, Matthew G, Johnson, Jill, Fiedler-Kelly, Christopher J, Bruno, Elizabeth G, Rhee, Carisa De, Anda, Hwa-Ping, Feng
Publikováno v:
The Journal of Clinical Pharmacology. 63:352-357
Probability of target attainment (PTA) analyses were conducted to support the recommended ceftolozane/tazobactam dosing regimens, adjusted for renal function, in patients with hospital-acquired/ventilator-associated bacterial pneumonia (HABP/VABP). P
Autor:
Hwa-Ping, Feng, Yogesh T, Patel, Zufei, Zhang, Jill, Fiedler-Kelly, Christopher J, Bruno, Elizabeth G, Rhee, Carisa, De Anda, Wei, Gao
Publikováno v:
The Journal of Clinical Pharmacology. 63:166-171
ASPECT-NP, a phase 3 trial of ceftolozane/tazobactam in hospital-acquired/ventilator-associated bacterial pneumonia (HABP/VABP), excluded patients with end-stage renal disease (ESRD). A modeling/simulation approach was undertaken to inform optimal do
Autor:
Carisa De Anda, Christopher Bruno, Hwa Ping Feng, Sumit Basu, Brian Yu, Elizabeth G. Rhee, Erin Jensen, Jennifer A. Huntington, Andrew F. Shorr, Marin H. Kollef, Wei Gao, Zufei Zhang
Publikováno v:
Critical Care, Vol 25, Iss 1, Pp 1-12 (2021)
Critical Care
Critical Care
Background The randomized, double-blind, phase 3 ASPECT-NP trial evaluated the efficacy of 3 g of ceftolozane/tazobactam (C/T) versus 1 g of meropenem infused every 8 h for 8 to 14 days for treatment of adults with hospital-acquired bacterial pneumon
Autor:
Wei, Gao, Julie, Passarell, Yogesh T, Patel, Zufei, Zhang, Gina, Lin, Jill, Fiedler-Kelly, Christopher J, Bruno, Elizabeth G, Rhee, Carisa S, De Anda, Hwa-Ping, Feng
Publikováno v:
Antimicrobial Agents and Chemotherapy. 66
An exposure–efficacy analysis of the phase 3 ASPECT-NP trial was performed to evaluate the relationship between plasma exposure of ceftolozane and tazobactam and efficacy endpoints (primary: 28-day all-cause mortality; key secondary: clinical cure
Autor:
Ednan K. Bajwa, Dawn Cislak, John Palcza, Hwa-ping Feng, Eric J. Messina, Tom Reynders, Jean-François Denef, Vasile Corcea, Eseng Lai, S. Aubrey Stoch
Publikováno v:
Respiratory medicine. 206
Novel therapeutics for pulmonary arterial hypertension (PAH) with improved safety/tolerability profiles are needed to address continued high rates of morbidity/mortality.This Phase 1 study evaluated efficacy/safety of inhaled single-dose MK-5475, an
Autor:
Na Liu, Xiaohong Wang, Jixiang Zhu, Sumit Basu, Yudong Wei, Bei Yan, Hui Wang, Francheska Colon-Gonzalez, Hwa-Ping Feng, Fang Sun, Haiyan Li, Yanqiao Zang
Publikováno v:
International Journal of Antimicrobial Agents. 61:106717
Autor:
Christine Fandozzi, Deborah Panebianco, Luzelena Caro, Dennis Wolford, Zifang Guo, Iain P. Fraser, Dennis Swearingen, Vanessa Levine, Hwa-Ping Feng, Thomayant Prueksaritanont, Joan R. Butterton, Marian Iwamoto, Wendy W. Yeh
Publikováno v:
Clinical Drug Investigation. 41:133-147
Many people infected with hepatitis C virus have comorbidities, including hypercholesterolemia, that are treated with statins. In this study, we evaluated the drug–drug interaction potential of the hepatitis C virus inhibitors elbasvir (EBR) and gr
Autor:
Hwa-Ping Feng, Patel, Yogesh T., Zufei Zhang, Fiedler-Kelly, Jill, Bruno, Christopher J., Rhee, Elizabeth G., De Anda, Carisa, Wei Gao
Publikováno v:
Journal of Clinical Pharmacology; Feb2023, Vol. 63 Issue 2, p166-171, 6p